New peptide drug shows promise for obesity and diabetes in early trial
NCT ID NCT04838405
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 39 times
Summary
This early-stage trial tested a new drug called CT-388 in 129 overweight or obese adults, including some with type 2 diabetes. The study aimed to check the drug's safety and how the body processes it, while also measuring weight loss and blood sugar changes. Participants received either CT-388 or a placebo by injection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Carmot Clinical Research Unit 101
Perth, Western Australia, 6009, Australia
-
Carmot Clinical Research Unit 105
Monterrey, Nuevo León, 66260, Mexico
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CT-388 (a synthetic peptide)
What this could lead to
If successful, CT-388 could become a new treatment for obesity and type 2 diabetes, helping with weight loss and blood sugar control.
What could go wrong
This is an early Phase 1 trial focused on safety, so it is too soon to know if CT-388 works. Side effects are possible, and the results may not lead to an approved treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.